Related Experiment Video
Updated: Aug 6, 2026
09:57
Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Perampanel Monotherapy in Epileptic Children: A Systematic Review with Pooled Descriptive Analysis
1Pediatric and Neurology Care Clinic (Private), Agartala, Tripura, 799001, India.
Journal of Child Neurology
|July 24, 2026
Summary
Perampanel monotherapy is effective for pediatric epilepsy, showing high responder and seizure freedom rates. This systematic review highlights its tolerable safety profile in children aged 2-16 years.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Epilepsy is a common neurological disorder in children.
- Perampanel is an antiepileptic drug used for epilepsy treatment.
- Understanding its efficacy and safety in pediatric monotherapy is crucial.
Purpose of the Study:
- To systematically review and analyze data on perampanel monotherapy in children with epilepsy.
- To assess the efficacy, safety, and retention rates of perampanel in this population.
Main Methods:
- Systematic review and pooled descriptive analysis of 12 studies (8 retrospective, 4 prospective).
- Included 850 children (aged 2-16 years) with epilepsy.
- Searched PubMed adhering to PRISMA guidelines.
Main Results:
- Predominantly focal seizures (86.71%) were observed.
- Perampanel maintenance doses ranged from 1.5 to 12.0 mg/day.
- High responder (78%), seizure freedom (72%), and retention (79%) rates at 12 months were reported with a tolerable safety profile.
Conclusions:
- Perampanel monotherapy demonstrates promising efficacy and a favorable safety profile in children with epilepsy.
- It may serve as an effective initial monotherapy option for pediatric epilepsy management.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:22Epilepsy ll: Types
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.